NURS 676 Advanced Pharmacology Midterm Exam (WCU)
@Question And Answers
What is the first line drug for a patient with hypothyroidism? - ANS-
Levothyroxine, a thyroid hormone
What is the first line drug for a patient with hyperthryoidism? - ANS-
Methimazole, an antithyroid agent
What is the first line drug for a pregnant patient with diabetes? -
ANS-Insulins that are rapid or short acting that are hum- derivatives.
What should patients HbA1C levels be below? - ANS-6.5%
Alendronate - ANS-Class: Bisphosphanate used to treat
osteoporosis and Paget's dx
MOA: Inhibits osteoclastic activity, increases bone density.
Tiludronate - ANS-Class: Bisphosphanate used to treat
osteoporosis and Paget's dx
MOA: Inhibits osteoclastic activity, increases bone density.
T or F: Amitriptylline will increase the concentration of
norepinephrine in the synapse - ANS-True
T or F: Haloperidol is a high potency antipsychotic which blocks
dopamine receptors? - ANS-True
T or F: Glipizide inhibits the dipeptidyl peptidase 4 enzyme? - ANS-
False
,T or F: A decreased concentration of TSH is commonly treated with
levothyroxine. - ANS-False
What is one long acting form of insulin? - ANS-Glargine or Detemir
,Lispro - ANS-Class: Rapid acting insulin for hyperglycemia
MOA: Onset 5 minutes; peaks 5 minutes; duration 4-5 hours
Aspart - ANS-Class: Rapid acting insulin for hyperglycemia
MOA: Onset 5 minutes; peaks 5 minutes; duration 4-5 hours
Regular - ANS-Class: Short acting insulin for hyperglycemia
MOA: Onset 30-45 minutes; peaks 3-4 hours; duration 4-10 hours
NPH - ANS-Class: Intermediate insulin for hyperglycemia
MOA: Onset 30 minutes-1 hour; peaks 4-10 hours; duration 12-24
hours
Glargine - ANS-Class: Long acting insulin for hyperglycemia
MOA: Onset 2-4 hours; does not have a peak, duration 24 hours
Detemir - ANS-Class: Long acting insulin for hyperglycemia
MOA: Onset 2-4 hours; does not have a peak, duration 24 hours
Glipizide - ANS-Class: Short acting Sulfonylurea for an insufficient
production of insulin in DM2
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
Glyburide - ANS-Class: Sulfonylurea for an insufficient production
of insulin in DM2
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
Chlorpropamide - ANS-Class: Sulfonylurea for an insufficient
production of insulin in DM2; off label for neurogenic DI
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
, Metformin - ANS-Class: Biguanide, first line drug for DM2
MOA: Decreases glucose production in liver, decreases GI glucose
absorption and improves insulin sensitivity by increasing peripheral
glucose uptake and utilization; does not stimulate insulin release
for beta cells; inhibits platelet aggregation and reduces blood
viscosity.
Acarbose - ANS-Class: Alpha Glucosidase Inhibitor; third-line for
DM2 in insulin resistant patients
MOA: Inhibits absorption of CHO in GI, lowers BG levels after meals
Miglitol - ANS-Class: Alpha Glucosidase Inhibitor; third-line for DM2
in insulin resistant patients
MOA: Inhibits absorption of CHO in GI, lowers BG levels after meals
Sitagliptin - ANS-Class: Dipeptidyl Peptidase 4 Inhibitor for DM2
MOA: Inhibits DPP4, breaks down GLP1 and GIP which are released
in response to a meal; leads to increase in secretion of insulin and
suppresses the release of glucagon by the pancreas; promotes pre
and postprandial glucose levels.
Saxaglipin - ANS-Class: Dipeptidyl Peptidase 4 Inhibitor for DM2
MOA: Inhibits DPP4, breaks down GLP1 and GIP which are released
in response to a meal; leads to increase in secretion of insulin and
suppresses the release of glucagon by the pancreas; promotes pre
and postprandial glucose levels.
Exenatide - ANS-Class: Glucagon Like Peptide 1 Agonist for DM2
MOA: Promotes insulin release from pancreatic beta cells in the
presence of elevated glucose concentrations.
@Question And Answers
What is the first line drug for a patient with hypothyroidism? - ANS-
Levothyroxine, a thyroid hormone
What is the first line drug for a patient with hyperthryoidism? - ANS-
Methimazole, an antithyroid agent
What is the first line drug for a pregnant patient with diabetes? -
ANS-Insulins that are rapid or short acting that are hum- derivatives.
What should patients HbA1C levels be below? - ANS-6.5%
Alendronate - ANS-Class: Bisphosphanate used to treat
osteoporosis and Paget's dx
MOA: Inhibits osteoclastic activity, increases bone density.
Tiludronate - ANS-Class: Bisphosphanate used to treat
osteoporosis and Paget's dx
MOA: Inhibits osteoclastic activity, increases bone density.
T or F: Amitriptylline will increase the concentration of
norepinephrine in the synapse - ANS-True
T or F: Haloperidol is a high potency antipsychotic which blocks
dopamine receptors? - ANS-True
T or F: Glipizide inhibits the dipeptidyl peptidase 4 enzyme? - ANS-
False
,T or F: A decreased concentration of TSH is commonly treated with
levothyroxine. - ANS-False
What is one long acting form of insulin? - ANS-Glargine or Detemir
,Lispro - ANS-Class: Rapid acting insulin for hyperglycemia
MOA: Onset 5 minutes; peaks 5 minutes; duration 4-5 hours
Aspart - ANS-Class: Rapid acting insulin for hyperglycemia
MOA: Onset 5 minutes; peaks 5 minutes; duration 4-5 hours
Regular - ANS-Class: Short acting insulin for hyperglycemia
MOA: Onset 30-45 minutes; peaks 3-4 hours; duration 4-10 hours
NPH - ANS-Class: Intermediate insulin for hyperglycemia
MOA: Onset 30 minutes-1 hour; peaks 4-10 hours; duration 12-24
hours
Glargine - ANS-Class: Long acting insulin for hyperglycemia
MOA: Onset 2-4 hours; does not have a peak, duration 24 hours
Detemir - ANS-Class: Long acting insulin for hyperglycemia
MOA: Onset 2-4 hours; does not have a peak, duration 24 hours
Glipizide - ANS-Class: Short acting Sulfonylurea for an insufficient
production of insulin in DM2
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
Glyburide - ANS-Class: Sulfonylurea for an insufficient production
of insulin in DM2
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
Chlorpropamide - ANS-Class: Sulfonylurea for an insufficient
production of insulin in DM2; off label for neurogenic DI
MOA: Stimulates insulin release form beta cells, all potentiate
effects of ADH.
, Metformin - ANS-Class: Biguanide, first line drug for DM2
MOA: Decreases glucose production in liver, decreases GI glucose
absorption and improves insulin sensitivity by increasing peripheral
glucose uptake and utilization; does not stimulate insulin release
for beta cells; inhibits platelet aggregation and reduces blood
viscosity.
Acarbose - ANS-Class: Alpha Glucosidase Inhibitor; third-line for
DM2 in insulin resistant patients
MOA: Inhibits absorption of CHO in GI, lowers BG levels after meals
Miglitol - ANS-Class: Alpha Glucosidase Inhibitor; third-line for DM2
in insulin resistant patients
MOA: Inhibits absorption of CHO in GI, lowers BG levels after meals
Sitagliptin - ANS-Class: Dipeptidyl Peptidase 4 Inhibitor for DM2
MOA: Inhibits DPP4, breaks down GLP1 and GIP which are released
in response to a meal; leads to increase in secretion of insulin and
suppresses the release of glucagon by the pancreas; promotes pre
and postprandial glucose levels.
Saxaglipin - ANS-Class: Dipeptidyl Peptidase 4 Inhibitor for DM2
MOA: Inhibits DPP4, breaks down GLP1 and GIP which are released
in response to a meal; leads to increase in secretion of insulin and
suppresses the release of glucagon by the pancreas; promotes pre
and postprandial glucose levels.
Exenatide - ANS-Class: Glucagon Like Peptide 1 Agonist for DM2
MOA: Promotes insulin release from pancreatic beta cells in the
presence of elevated glucose concentrations.
